<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR59">
 <label>59.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zinman</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Wanner</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Lachin</surname>
    <given-names>JM</given-names>
   </name>
   <name>
    <surname>Fitchett</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Bluhmki</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Hantel</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Mattheus</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Devins</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Johansen</surname>
    <given-names>OE</given-names>
   </name>
   <name>
    <surname>Woerle</surname>
    <given-names>HJ</given-names>
   </name>
   <name>
    <surname>Broedl</surname>
    <given-names>UC</given-names>
   </name>
   <name>
    <surname>Inzucchi</surname>
    <given-names>SE</given-names>
   </name>
  </person-group>
  <article-title>EMPA-REG OUTCOME investigators. empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes</article-title>
  <source>N Engl J Med</source>
  <year>2015</year>
  <volume>373</volume>
  <fpage>2117</fpage>
  <lpage>2128</lpage>
  <pub-id pub-id-type="doi">10.1056/NEJMoa1504720</pub-id>
  <?supplied-pmid 26378978?>
  <pub-id pub-id-type="pmid">26378978</pub-id>
 </element-citation>
</ref>
